<prompt> Answer this question truthfullyCan you give an example of ATLAS that is provided by JC?  <response>: <reason> All comparisons are rivaroxaban 2.5mg vs. rivaroxaban 5mg vs. placebo 2.5mg vs. placebo 5mg vs. placebo.Composite of CV mortality, MI, or stroke efficacy 9.1 vs. 8.8 vs. 10.7 HR 0.84; P0.02 HR 0.85; P0.03TIMI major bleeding not associated with CABG safety 1.8 vs. 2.4 vs. 0.6 HR 3.46; P0.001 HR 4.47; P0.001Composite of all-cause mortality, MI or stroke 9.3 vs. 9.1 vs. 11.0 HR 0.83; P0.02 HR 0.84; P0.02CV mortality 2.7 vs. 4.0 vs. 4.1 HR 0.66; P0.002 HR 0.94; P0.63All-cause mortality 2.9 vs. 4.4 vs. 4.5 HR 0.68; P0.002 HR 0.95; P0.66MI 6.1 vs. 4.9 vs. 6.6 HR 0.90; P0.27 HR 0.79; P0.02Any stroke 1.4 vs. 1.7 vs. 1.2 HR 1.13; P0.56 HR 1.34; P0.15Ischemic stroke 1.4 vs. 1.7 vs. 1.2 HR 0.89; P0.64 HR 1.05; P0.84Stent thrombosis 2.2 vs. 2.3 vs. 2.9 HR 0.65; P0.02 HR 0.73; P0.08Good follow-up Complete: 85 vs. 84 vs. 85 Death: 3 vs. 4 vs. 4 Total: 88 vs. 87 vs. 89Bad follow-up Consent withdrawn: 9 vs. 9 vs. 8 Lost: 0.2 vs. 0.3 vs. 0.3 Other: 3 vs. 4 vs. 3 Total: 11 vs. 12 vs. 13TIMI minor bleeding 0.9 vs. 1.6 vs. 0.5 HR 1.62; P0.09 HR 2.52; P0.001TIMI bleeding requiring medical attention 12.9 vs. 16.2 vs. 7.5 HR 1.79; P0.001 HR 2.39; P0.001ICH 0.4 vs. 0.7 vs. 0.2 HR 2.83; P0.04 HR 3.74; P0.005Fatal bleeding 0.1 vs. 0.4 vs. 0.2 HR 0.67; P0.45 HR 1.72; P0.20Reduction in primary efficacy outcome with rivaroxaban was consistent among subgroups except for patients with history of stroke or TIA. 